BROWN RUDNICK LLP for APOTEX CORPORATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues relating to Risk Evaluation and Mitigation Strategies; Drug Quality and Security Act ( P.L. 113-54); FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (RIN:0910-AG94).
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BOWLIN | — |
| LISA LAYMAN | — |
| HENRY W MENN | — |
Health Issues HCR
Fair and Immediate Release of Generic Drugs Act and Preserve Access to Affordable Generics Act
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BOWLIN | Prof Staff, House Cmte on Ed & Workforce 99-01 |
| LISA LAYMAN | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.